Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 41.95B | 41.22B | 40.73B | 40.33B | 40.11B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.95B | 41.22B | 40.73B | 40.33B | 40.11B |
| Cost of Revenue | 18.64B | 18.17B | 18.08B | 18.04B | 17.92B |
| Gross Profit | 23.31B | 23.04B | 22.64B | 22.29B | 22.19B |
| SG&A Expenses | 11.11B | 10.90B | 10.74B | 10.57B | 10.39B |
| Depreciation & Amortization | 1.88B | 1.89B | 1.92B | 1.95B | 1.97B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.45B | 33.62B | 33.35B | 33.20B | 32.89B |
| Operating Income | 7.50B | 7.60B | 7.38B | 7.13B | 7.22B |
| Income Before Tax | 7.01B | 6.78B | 6.51B | 6.54B | 6.66B |
| Income Tax Expenses | -6.39B | 1.01B | 952.00M | 908.00M | 941.00M |
| Earnings from Continuing Operations | 13.40K | 5.77K | 5.56K | 5.63K | 5.72K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.40B | 5.77B | 5.56B | 5.63B | 5.72B |
| EBIT | 7.50B | 7.60B | 7.38B | 7.13B | 7.22B |
| EBITDA | 10.71B | 10.83B | 10.62B | 10.37B | 10.46B |
| EPS Basic | 7.65 | 3.29 | 3.17 | 3.21 | 3.27 |
| Normalized Basic EPS | 2.56 | 2.61 | 2.51 | 2.44 | 2.47 |
| EPS Diluted | 7.64 | 3.29 | 3.17 | 3.21 | 3.26 |
| Normalized Diluted EPS | 2.55 | 2.60 | 2.51 | 2.44 | 2.47 |
| Average Basic Shares Outstanding | 6.98B | 6.98B | 6.98B | 6.98B | 6.98B |
| Average Diluted Shares Outstanding | 6.99B | 7.00B | 7.00B | 7.00B | 7.00B |
| Dividend Per Share | 2.24 | 2.20 | 2.16 | 2.12 | 2.08 |
| Payout Ratio | 28.62% | 65.30% | 66.47% | 64.35% | 62.14% |
